BioWorld

April 30, 2004

Cytokinetics IPO Raises $90M For Late-Stage Cancer Drugs

Cytokinetics Inc. priced its initial public offering Thursday, raising $89.7 million, slightly more than it expected to raise when it filed in January. (BioWorld Today) Read More

OrthoLogic Expanding Peptide Platform Via Chrysalis Buyout

Members Of Congress Petition Bush For ESC Policy Change

SkyePharma Divests Dermatology Assets, Sells Debt, Reports Loss

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

Alicorn synthesizes new AAK1 inhibitors

BioWorld Science

Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

Illustration of glucose in the blood stream

CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research

BioWorld Science

Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...

Saniona reports preclinical data for SAN-2668

BioWorld Science

Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...